

Healthcare equipment is undervalued based on historical averages, while other subsectors are slightly overvalued. The iShares Global Healthcare ETF offers diversified global healthcare exposure, with 72% in US companies and 110 holdings. Despite lower company-specific risk and better value, IXJ has underperformed XLV by about 2% annualized over both long and short timeframes.

Fidelity MSCI Health Care Index ETF has a significantly lower expense ratio than iShares Global Healthcare ETF. iShares Global Healthcare ETF provides exposure to international healthcare markets, whereas the Fidelity fund focuses on U.S. equities.

XLV has a significantly lower expense ratio of 0.08% compared to IXJ's 0.38%. IXJ provides broader exposure with 110 holdings across global markets, while XLV concentrates on 60 domestic S&P 500 stocks.

iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered stronger total returns over the last year but experiences significantly higher maximum drawdowns.

South Korean stocks fell sharply on Thursday as Brent crude held above $100 a barrel, pushing the KOSPI back below the 7,000 mark just a day after it reclaimed the level for the first time in more than a month. The benchmark was down 1.28% at 6,961.23 by late morning in Seoul.

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

The Vanguard Health Care ETF (VHT) is significantly cheaper to own than the iShares Global Healthcare ETF (IXJ). IXJ offers exposure to international companies, while VHT focuses more heavily on the U.S. market.

iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly deeper maximum drawdown.